Amgen’s Four-Year Denosumab Data Shows Bone Density Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth also presents the first Phase III fracture data on its potential competitor Viviant.
You may also be interested in...
Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio
Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.
Amgen Presents Positive Results In First Phase III For Denosumab At San Antonio
Firm plans to file BLA in late 2008, early 2009 for post-menopausal osteoporosis and treatment induced osteopenia.
Wyeth’s Viviant “Approvable” For Prevention Of Postmenopausal Osteoporosis
Firm continues to plan an additional submission this year for an osteoporosis treatment claim.